Show simple item record

dc.contributor.authorBesada, Emilio
dc.contributor.authorKoldingsnes, Wenche
dc.contributor.authorNossent, Hans
dc.date.accessioned2016-03-04T10:45:46Z
dc.date.available2016-03-04T10:45:46Z
dc.date.issued2015-06-25
dc.description.abstractObjective. Chronic nasal carriage of Staphylococcus aureus (SA) increases the risk of relapse while Rituximab (RTX) is an effective agent for inducing and maintaining remission in patients with Granulomatosis with polyangiitis (GPA). We investigated whether B cell depletion and hypogammaglobulinemia that occur during RTX treatment increase the risk of chronic SA nasal carriage and subsequent disease flares, in GPA patients on long-term RTX maintenance therapy. <p>Methods. Retrospective cohort study from a disease registry involving 29 GPA patients receiving RTX maintenance (median RTX dose of 9 g) during a median period of 49 months. Nasal swabs were collected prior and during RTX for a median of 3 and 9 swabs respectively. Persistent SA nasal carriage was defined with the presence of SA in more than 75% of nasal swabs. <p>Results. SA nasal carriage did not change during RTX (p = 0.297). However, the rate of positive nasal swabs in GPA patients with transient SA nasal carriage during RTX maintenance increased from 0 prior RTX to 0.42 during RTX (p = 0.017). Persistent SA nasal carriage did not increase the risk of relapses (p = 0.844), of hypogammaglobulinemia (p = 0.122) and of severe infections (p = 0.144), but reduced the risk of chronic infections (p = 0.044). Change in SA carriage status during RTX did not influence the risk of relapses (p = 0.756), hypogammaglobulinamia (p = 0.474) and infections, either severe (p = 0.913) or chronic (p = 0.121). <p>Conclusion. Long-term RTX maintenance therapy in GPA patients did not significantly influence SA nasal carriage status. Persistent SA carriage during long-term RTX treatment did not seem to increase the risk of relapses, but seemed to decrease the risk of hypogammaglobulinemia associated chronic infections.en_US
dc.identifier.citationPeerJ 2015en_US
dc.identifier.cristinIDFRIDAID 1251187
dc.identifier.doi10.7717/peerj.1051
dc.identifier.issn2167-8359
dc.identifier.urihttps://hdl.handle.net/10037/8686
dc.identifier.urnURN:NBN:no-uit_munin_8179
dc.language.isoengen_US
dc.publisherPeerJen_US
dc.relation.urihttps://dx.doi.org/10.7717/peerj.1051en_US
dc.rights.accessRightsopenAccess
dc.subjectRituximaben_US
dc.subjectGranulomatosis with polyangiitisen_US
dc.subjectVasculitisen_US
dc.subjectRelapseen_US
dc.subjectInfectionsen_US
dc.subjectHypogammaglobulinemiaen_US
dc.subjectMaintenanceen_US
dc.subjectNasal carriageen_US
dc.subjectMicrobiomeen_US
dc.subjectStaphylococcus aureusen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.titleStaphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitisen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record